Rovida Advisors’s Gilead Sciences GILD Stock Holding History

Rovida Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-60,000	Closed	-$3.88M	–	51
2021 Q1	$3.88M	Hold	60,000	–	–	0.18%	39
2020 Q4	$3.49M	Buy	+60,000	New	+$3.62M	0.21%	32
2017 Q1	–	Sell	-200,000	Closed	-$14.3M	–	20
2016 Q4	$14.3M	Buy	+200,000	New	+$14.9M	3.18%	13

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Rovida Advisors's GILD Position: Q2 2021 in Review

Rovida Advisors sold out of Gilead Sciences (GILD) in Q2 2021, closing a stake of 60,000 shares — an estimated $3.88M sold.

Rovida Advisors first reported a position in GILD in Q4 2016 and held it in 3 quarters. The position peaked at $14.3M in Q4 2016. 1,544 funds tracked by Wall St. Rank hold GILD as of Q2 2021.

Rovida Advisors reported no remaining Gilead Sciences position as of Q2 2021 after selling out during the quarter.
Rovida Advisors sold 60,000 Gilead Sciences shares in Q2 2021, an estimated $3.88M.
Rovida Advisors first reported a position in Gilead Sciences in Q4 2016 and held it in 3 quarters.
Rovida Advisors's Gilead Sciences position peaked at $14.3M in Q4 2016.
1,544 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2021.

Based on Rovida Advisors's 13F filing for Q2 2021, filed 10 Aug 2021.